Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: An indirect comparison meta-analysis

Curtis L. Cooper, Eric Druyts, Kristian Thorlund, Jean B. Nachega, Antoine C. El Khoury, Christopher O'Regan, Edward J. Mills

Research output: Contribution to journalArticle

Abstract

Background: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis. Methods: Published phase II and phase III randomized placebo-controlled trials examining the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult populations were included. The primary outcomes were sustained virologic response, relapse, and discontinuation of all study drugs. Secondary outcomes included the adverse events of anemia, neutropenia, rash, and pruritus. Results: Four boceprevir trials and six telaprevir trials were included. No significant differences were observed for sustained virologic response among either naïve (relative risk [RR] 1.14, 95% confidence interval [CI] 0.93-1.37, P = 0.20) or experienced patients (RR 0.81, 95% CI 0.52-1.23, P = 0.30). Similarly, for relapse among naïve (RR 0.80, 95% CI 0.18-3.45, P = 0.77) and experienced patients (RR 1.71, 95% CI 0.90-3.24, P = 0.10), or discontinuation of therapy for naïve (RR 0.80, 95% CI 0.28-2.29, P = 0.72) and experienced patients (RR 0.88, 95% CI 0.69-1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and boceprevir was more likely to be associated with neutropenia in certain patient populations. Conclusion: Boceprevir and telaprevir appear comparable in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy durations and response-guided therapy durations.

Original languageEnglish (US)
Pages (from-to)105-130
Number of pages26
JournalTherapeutics and Clinical Risk Management
Volume8
DOIs
StatePublished - 2012

Fingerprint

Chronic Hepatitis C
contagious disease
Meta-Analysis
confidence
Genotype
Confidence Intervals
relapse
Infection
Pruritus
Exanthema
Neutropenia
Recurrence
Therapeutics
Interferons
Ribavirin
Viruses
Interferon-alpha
Hepacivirus
Population
telaprevir

Keywords

  • Boceprevir
  • Direct-acting antivirals
  • Hepatitis C
  • Meta-analysis
  • Telaprevir

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection : An indirect comparison meta-analysis. / Cooper, Curtis L.; Druyts, Eric; Thorlund, Kristian; Nachega, Jean B.; El Khoury, Antoine C.; O'Regan, Christopher; Mills, Edward J.

In: Therapeutics and Clinical Risk Management, Vol. 8, 2012, p. 105-130.

Research output: Contribution to journalArticle

Cooper, Curtis L. ; Druyts, Eric ; Thorlund, Kristian ; Nachega, Jean B. ; El Khoury, Antoine C. ; O'Regan, Christopher ; Mills, Edward J. / Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection : An indirect comparison meta-analysis. In: Therapeutics and Clinical Risk Management. 2012 ; Vol. 8. pp. 105-130.
@article{c6adf3a9f0b8478b8ab242e68e980eda,
title = "Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: An indirect comparison meta-analysis",
abstract = "Background: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis. Methods: Published phase II and phase III randomized placebo-controlled trials examining the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult populations were included. The primary outcomes were sustained virologic response, relapse, and discontinuation of all study drugs. Secondary outcomes included the adverse events of anemia, neutropenia, rash, and pruritus. Results: Four boceprevir trials and six telaprevir trials were included. No significant differences were observed for sustained virologic response among either na{\"i}ve (relative risk [RR] 1.14, 95{\%} confidence interval [CI] 0.93-1.37, P = 0.20) or experienced patients (RR 0.81, 95{\%} CI 0.52-1.23, P = 0.30). Similarly, for relapse among na{\"i}ve (RR 0.80, 95{\%} CI 0.18-3.45, P = 0.77) and experienced patients (RR 1.71, 95{\%} CI 0.90-3.24, P = 0.10), or discontinuation of therapy for na{\"i}ve (RR 0.80, 95{\%} CI 0.28-2.29, P = 0.72) and experienced patients (RR 0.88, 95{\%} CI 0.69-1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and boceprevir was more likely to be associated with neutropenia in certain patient populations. Conclusion: Boceprevir and telaprevir appear comparable in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy durations and response-guided therapy durations.",
keywords = "Boceprevir, Direct-acting antivirals, Hepatitis C, Meta-analysis, Telaprevir",
author = "Cooper, {Curtis L.} and Eric Druyts and Kristian Thorlund and Nachega, {Jean B.} and {El Khoury}, {Antoine C.} and Christopher O'Regan and Mills, {Edward J.}",
year = "2012",
doi = "10.2147/TCRM.S29830",
language = "English (US)",
volume = "8",
pages = "105--130",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection

T2 - An indirect comparison meta-analysis

AU - Cooper, Curtis L.

AU - Druyts, Eric

AU - Thorlund, Kristian

AU - Nachega, Jean B.

AU - El Khoury, Antoine C.

AU - O'Regan, Christopher

AU - Mills, Edward J.

PY - 2012

Y1 - 2012

N2 - Background: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis. Methods: Published phase II and phase III randomized placebo-controlled trials examining the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult populations were included. The primary outcomes were sustained virologic response, relapse, and discontinuation of all study drugs. Secondary outcomes included the adverse events of anemia, neutropenia, rash, and pruritus. Results: Four boceprevir trials and six telaprevir trials were included. No significant differences were observed for sustained virologic response among either naïve (relative risk [RR] 1.14, 95% confidence interval [CI] 0.93-1.37, P = 0.20) or experienced patients (RR 0.81, 95% CI 0.52-1.23, P = 0.30). Similarly, for relapse among naïve (RR 0.80, 95% CI 0.18-3.45, P = 0.77) and experienced patients (RR 1.71, 95% CI 0.90-3.24, P = 0.10), or discontinuation of therapy for naïve (RR 0.80, 95% CI 0.28-2.29, P = 0.72) and experienced patients (RR 0.88, 95% CI 0.69-1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and boceprevir was more likely to be associated with neutropenia in certain patient populations. Conclusion: Boceprevir and telaprevir appear comparable in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy durations and response-guided therapy durations.

AB - Background: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis. Methods: Published phase II and phase III randomized placebo-controlled trials examining the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult populations were included. The primary outcomes were sustained virologic response, relapse, and discontinuation of all study drugs. Secondary outcomes included the adverse events of anemia, neutropenia, rash, and pruritus. Results: Four boceprevir trials and six telaprevir trials were included. No significant differences were observed for sustained virologic response among either naïve (relative risk [RR] 1.14, 95% confidence interval [CI] 0.93-1.37, P = 0.20) or experienced patients (RR 0.81, 95% CI 0.52-1.23, P = 0.30). Similarly, for relapse among naïve (RR 0.80, 95% CI 0.18-3.45, P = 0.77) and experienced patients (RR 1.71, 95% CI 0.90-3.24, P = 0.10), or discontinuation of therapy for naïve (RR 0.80, 95% CI 0.28-2.29, P = 0.72) and experienced patients (RR 0.88, 95% CI 0.69-1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and boceprevir was more likely to be associated with neutropenia in certain patient populations. Conclusion: Boceprevir and telaprevir appear comparable in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy durations and response-guided therapy durations.

KW - Boceprevir

KW - Direct-acting antivirals

KW - Hepatitis C

KW - Meta-analysis

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84862550129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862550129&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S29830

DO - 10.2147/TCRM.S29830

M3 - Article

C2 - 22442631

AN - SCOPUS:84862550129

VL - 8

SP - 105

EP - 130

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -